Homocysteine level and other biochemical parameters in cardiovascular disease patients with diabetes mellitus

Medical Science Monitor

Volumn 9, Issue 12, 2003, Pages

  Ajabnoor, Mohamed ^a   Al Ama, Mohamed ^a   Banjar, Zainy ^a   Rafee, Adel Abdul ^a   Sheweita, Salah ^a,b  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^b ALEXANDRIA UNIVERSITY   (Egypt)

Author keywords

Atherosclerosis; Cholesterol; Diabetes; Homocysteine

Indexed keywords

CHOLESTEROL; CREATININE; CYANOCOBALAMIN; FOLIC ACID ANTAGONIST; HIGH DENSITY LIPOPROTEIN; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN; UREA;

AMINO ACID BLOOD LEVEL; ARTICLE; ATHEROSCLEROSIS; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIET RESTRICTION; DIET SUPPLEMENTATION; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; INFORMED CONSENT; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; SAUDI ARABIA; UREA BLOOD LEVEL; VITAMIN BLOOD LEVEL;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; FEMALE; FOLIC ACID; HOMOCYSTEINE; HUMANS; LIPIDS; MALE; RISK FACTORS; VITAMIN B 12;

EID: 17944401291     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Graham IM, Daly LE, Refsum HM et al: Plasma homocysteine as a risk factor for vascular disease: the European concerted action project. JAMA, 1997; 277: 1775-81
2. Morris MS, Fava M, Jacques PF et al: Depression and Folate Status in the US Population. Psychother Psychosom, 2003; 72(2): 80-7
3. Bates CJ, Schneede J, Mishra G et al: Relationship between methylmalonic acid, homocysteine, vitamin B(12) intake and status and socio-economic indices, in a subset of participants in the British National Diet and Nutrition Survey of people aged 65 years and over. Eur J Clin Nutr 2003; 57(2): 349-57
4. Stampfer MJ, Malinow MR, Willett WC: A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA, 1992; 268: 877-881
5. Nygard O, Nordrehaug JE, Refsum H: Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med, 1997; 337: 230-236
6. Rasmussen K, Moller J, Lyngbak M et al: Age- and gender-specific reference intervals for total homocysteine and methylmalonic acid in plasma before and after vitamin supplementation. Clin Chem, 1996; 42: 630-636
7. Alfthan G, Aro A, Gey KF: Plasma homocysteine and cardiovascular disease mortality. Lancet., 1997; 349: 397
8. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG: A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA, 1995; 274: 1049-57
9. McCully Ks, Wilson RB: Homocysteine theory of barteiosclerosis. Atherosclerosis, 1975; 22: 215-27
10. Tasi JC, Perrella MA, Yoshizumi M: Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci USA, 1994; 91: 6369-6373
11. Wu KS, Chook P, Lolin YI: Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans. Circulation, 1997; 96: 2542-2544
12. Wu LL, Warnick GR, Wu JT et al: A rapid micro-scale procedure for determination of the total lipid profile. Clin Chem, 1988; 35: 1486-91
13. 12 concentrations and risk for early onset coronary artery disease. Am J Clin Nutr, 1994; 59: 940-8
14. Hopkins PN, Wu LL, Wu J et al: Higher plasma homocyst(e)ine and increased susceptibility to adverse effects of low folate in early familial coronary artery disease. Arterioscler Thromb Vasc Biol, 1995; 15: 1314-20
15. Morrison HI, Schaubel D, Desmeules M, Wigle DT: Serum folate and risk of fatal coronary heart disease. JAMA, 1996; 275: 1893-6
16. 6 and risk of myocardial infarction in US physicians. J Am Coll Nutr, 1996; 15: 136-43
17. Verhoef P, Kok FJ, Kruyssen DM et al: Plasma total homocysteine, B vitamins, and risk of coronary atherosclerosis. Arterioscler Thromb Vasc Biol, 1997; 17: 989-95
18. 6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA, 1998; 279: 359-64
19. Jacobsen DW, Gatautis VJ, Green R et al: Rapid HPLC determination of total homocysteine and other thiols in serum and plasma: sex differences and correlation with cobalamin and folate levels in normal subjects. Clin Chem, 1994; 40: 873-81
20. 6, folate nutritional status in men with hyperhomocysteinemia. Am J Clin Nutr 1993; 57: 47-53
21. Hultberg B, Berglund M, Andersson A, Frank A: Elevated plasma homocysteine in alcoholics. Alcohol Clin Exp Res, 1993; 17: 687-9
22. 6 status. Am J Clin Nutr, 1996; 63: 220-4
23. Schwartz CJ, Valente AJ, Sprague EA et al: Pathogenesis of the atherosclerotic lesion. Implications for diabetes mellitus. Diabetes Care, 1992; 15: 1156-1167
24. Vitoratos N, Kassanos D, Salamalekis E et al: Maternal homocysteine levels and plasma lipids in gestational diabetes: is there any relationship? J Obstet Gynaecol, 2002; 22(4): 366-9
25. Becker A, Kostense PJ, Bos G et al: Hyperhomocysteinaemia is associated with coronary events in type 2 diabetes. J Intern Med, 2003; 253: 293-300
26. American Diabetes Association: Role of cardiovascular risk factors in prevention and treatment of macrovascular disease in diabetes. Diabetes Care, 1993; 16: 72-78
27. Laakso M: Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes, 1999; 48: 937-942
28. Grundy SM, Benjamin IJ, Burke GL et al: Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation, 1999; 100: 1134-1146
29. Nishikawa T, Edelstein D, Du XL: Normalizing mitochondrial superoxide production blocks three pathways of hyperglycemic damage. Nature, 2000; 404: 787-790
30. Sheweita SA, Newairy AA, Mansour HA, Yousef MI: Effect of some hypoglycemic herbs on the activity of phase I and II drug-metabolizing enzymes in alloxan-induced diabetic rats. Toxicol, 2002; 174(2): 131-139
31. Newairy AA, Mansour HA, Yousef MI, Sheweita SA: Alteration of lipid profile in plasma and liver of diabetic rats: influence of hypoglycemic herbs. J Env Sci and Health Vlo B, 2002; 37 (5): 112-122
32. Mansour HA, Newairy AA, Yousef MI, Sheweita SA: Biochemical study on the effect of some Egyptian herbs in alloxan-induced diabetic rats. Toxicol, 2002; 170(3): 221-228
33. Frantzen F, Faaren AL, Alfheim I, Nordhei AK: An enzyme conversion immunoassay for determining total homocysteine in plasma or serum. Clin Chem, 1998; 44: 311-316
34. Wilson PW, D'Agostino RB, Levy D et al: Prediction of coronary heart disease using risk factor categories. Circulation, 1998; 97: 1837-1847
35. Wilson PW: Diabetes mellitus and coronary heart disease. Am J Kidney Disease, 1998; 32: S89-S100
36. McGill HC Jr, McMahan CA: Determinants of atherosclerosis in the young: Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Am J Cardiol, 1998; 82: 30T-36T
37. National Center for Health Statistics: Plan and operation of the second national health interview survey 1976-1980. In: Vital and Health Statistics. Washington, DC: US Government Printing Office; Ser. 1, No. 15, DHHS Publication, 1981; 81-1317
38. Guba SC, Fink LM, Fonseca V: Hyperhomocysteinemia: an emerging and important risk factor for thromboembolic and cardiovascular disease. Am J Clin Pathol, 1996; 106: 709-22
39. Bucala R, Mitchell R, Arnold K et al: Identification of the major site of apolipoprotein B modification by advanced glycosylation end products blocking uptake by the low density lipoprotein receptor. J Biol Chem, 1995; 270: 10828-10832
40. Bucala R, Makita Z, Koschinsky T et al: Lipid advanced glycosylation: Pathway for lipid oxidation in vivo. Proc Natl Acad Sci USA, 1993; 90: 6434-6438
41. Bucala R, Makita Z, Vega G et al: Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA, 1994; 91: 6441-9445
42. Klein RL, Laimins M, Lopes-Virella MF: Isolation, characterization, and metabolism of the glycated and nonglycated surfactions of low-density lipoproteins isolated from type I diabetic patients and nondiabetic subjects. Diabetes, 1995; 44: 1093-1098
43. Aronson D, Rayfield E: How hyperglycemia promotes atherosclerosis: molecular mechanisms. Cardiovascular Diabetol, 2002; 1: 1-10
44. Ferretti G, Bacchetti T, Marotti E, Curatola G: Effect of homocysteinylation on human high-density lipoproteins: a correlation with paraoxonase activity. Metabolism, 2003; 52(2): 146-51
45. Jer-Chia T, Perrella MA, Yoshizumi M: Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc. Natl. Acad. Sci. USA, 1994; 91: 6369-6373
46. Malinow MR, Bostom AG, Krauss RM: Homocyst(e)ine, diet, and cardiovascular disease: a statement for health care professionals from the Nutrition Committee, American Heart Association. Circulation, 2002; 99(1): 178-182
47. Auer J, Berent R, Weber T et al: Homocysteine and cardiovascular risk. Wien Med Wochenschr, 2001; 151: 25-28
48. Van Ede AE, Laan R.F, Blom HJ et al: Homocysteine and folate status in methotrexate-treated patients. Rheumatol, 2002; 41: 658-665
49. 12. Rev Invest Clin, 2001; 53: 141-151